Loading...

Table of Content

    20 January 2024, Volume 19 Issue 1
    Highlights in Stroke in 2023
    WANG Yongjun, XIONG Yunyun, LI Guangshuo, CAO Zhixin, WANG Wenjie, YAN Ran, WANG Liyuan, LU Zhengzhao, HAO Manjun
    2024, 19(1):  1-21.  DOI: 10.3969/j.issn.1673-5765.2024.01.001
    Asbtract ( )   PDF (4004KB) ( )  
    References | Related Articles | Metrics
    Cerebrovascular clinicians from different countries all over the world made great progress in the diagnosis and treatment of cerebral vascular diseases in recent years. Numerous high-quality clinical studies cover multiple fields and hotspots of cerebral vascular disease, such as thrombectomy/thrombolysis in the acute phase of ischemic stroke, intervention for atrial fibrillation, blood pressure management and other acute phase intervention measures, providing solid and reliable evidence-based medical evidence for clinical diagnosis and treatment in cerebral vascular disease, and promoting the reduction of cerebral vascular disease burden. This paper reviews the important clinical research progress in the field of cerebral vascular disease in 2023, helping readers better understand the advantages and great significance of these clinical studies, and looking forward to more and better cerebral vascular disease clinical studies in the future. 
    Construction and Development of Quality Control Indicator System for Single Disease
    YANG Xin, ZHANG Jing, LI Zixiao, WANG Yongjun
    2024, 19(1):  22-27.  DOI: 10.3969/j.issn.1673-5765.2024.01.002
    Asbtract ( )   PDF (1902KB) ( )  
    References | Related Articles | Metrics
    The single disease quality control indicators are benchmarks for evaluating the medical services quality and tools for continuous medical quality improvement. The construction and development of quality control indicators for single disease in China have gone through four stages: initial exploration, pilot application, promotion and rapid advancement. With the continuous deepening of single disease quality management, single disease quality control indicators will play a greater role in hospital evaluation, specialty construction and evaluation, and continuous improvement of medical quality. 
    Quality Control Indicators and Interpretation of Single Disease of Neurological Diseases  
    ZHANG Jing, YANG Xin
    2024, 19(1):  28-28. 
    Asbtract ( )   PDF (1789KB) ( )  
    Related Articles | Metrics
    Revision Process of Medical Quality Control Indicators in Cerebral Infarction 
    YANG Xin, LI Zixiao, WANG Yongjun
    2024, 19(1):  29-34.  DOI: 10.3969/j.issn.1673-5765.2024.01.003
    Asbtract ( )   PDF (2227KB) ( )  
    References | Related Articles | Metrics
    The medical quality control indicators in cerebral infarction were developed in 2008 and revised in 2012, 2015, 2018, and 2020, respectively. This indicator system is the standard for monitoring and evaluating the medical quality of cerebral infarction in China, and also a feedback tool for continuous improvement of medical quality of cerebral infarction. The indicators play an important role in medical quality control and management of cerebral infarction. 
    Medical Quality Control Indicators for Cerebral Infarction (2020 Edition)
    The Cerebrovascular Disease Working Group of National Center for Healthcare Quality Management in Neurological Diseases
    2024, 19(1):  35-43.  DOI: 10.3969/j.issn.1673-5765.2024.01.004
    Asbtract ( )   PDF (1524KB) ( )  
    References | Related Articles | Metrics
    The 2020 edition of the medical quality control indicators for cerebral infarction is revised based on the 2018 edition, including a total of 27 quality control indicators. Among them, 23 items (85%) were medical services process indicators, including assessment and examination on acute phase, cerebrovascular reperfusion treatment on acute phase, standardized treatment and prevention of complications, and secondary prevention, 4 items (15%) were outcome indicators after treatment of patients, focusing on mortality and postoperative functional recovery. The indicator system is mainly used to evaluate the quality of medical services provided by medical institutions for cerebral infarction patients, in order to promote the continuous improvement of medical quality for cerebral infarction. 
    Medical Quality Control Indicators for Intracerebral Hemorrhage
    The Cerebrovascular Disease Working Group of National Center for Healthcare Quality Management in Neurological Diseases
    2024, 19(1):  44-49.  DOI: 10.3969/j.issn.1673-5765.2024.01.005
    Asbtract ( )   PDF (1895KB) ( )  
    References | Related Articles | Metrics
    After systematically reviewing evidence-based medical evidence and domestic and foreign guidelines, and extensively consulting experts in clinical, rehabilitative and scientific research fields related to cerebral vascular diseases, the Cerebrovascular Disease Working Group of National Center for Healthcare Quality Management in Neurological Diseases, together with the Management and Improvement of Chinese Medical Care Quality on Stroke, Chinese Stroke Association, have formulated an indicator system for the medical quality control of intracerebral hemorrhage. The indicator system covers different aspects such as acute treatment of intracerebral hemorrhage, screening of etiology and complications, rehabilitation and long-term management. Quantitative evaluation of the quality control of the whole cycle of diagnosis and treatment of intracerebral hemorrhage was shown in the form of rate, which is conducive to the normalization and homogeneity construction of diagnosis and treatment of intracerebral hemorrhage across China.
    Interpretation of Medical Quality Control Indicators for Intracerebral Hemorrhage
    WANG Jing, LI Zixiao, DONG Qiang, ZHAO Xingquan
    2024, 19(1):  50-54.  DOI: 10.3969/j.issn.1673-5765.2024.01.006
    Asbtract ( )   PDF (1797KB) ( )  
    References | Related Articles | Metrics
    The incidence of intracerebral hemorrhage (ICH) is less than ischemic stroke, but its mortality and disability rate are high. In China, nearly 46% of patients with ICH died or left serious disability within one year. Therefore, it is particularly important to standardize the diagnosis and treatment of ICH. In 2018, the American Heart Association (AHA) /American Stroke Association (ASA) developed clinical management indicators for patients with ICH based on the higher level of evidence level Ⅰ or Ⅲ recommendations in the guidelines for the management of spontaneous ICH, translating the guidelines into clinically practical quantitative indicators. From July 2021, the National Center for Healthcare Quality Management in Neurological Diseases and the Management and Improvement of Chinese Medical Care Quality on Stroke, Chinese Stroke Association adopted the improved Delphi method and finally formulated an index system for medical quality control of ICH, including 11 indicators. This paper makes detailed interpretation of these 11 indicators in order to guide medical institutions to provide medical assistance for patients in the best time safely and effectively, improve the quality of medical assistance for patients with ICH, and improve the clinical outcome of patients.
    The Construction of the Medical Quality Control System for Epilepsy and Convulsive Status Epilepticus
    LU Lu, XIONG Weixi, ZHOU Dong
    2024, 19(1):  55-57.  DOI: 10.3969/j.issn.1673-5765.2024.01.007
    Asbtract ( )   PDF (1870KB) ( )  
    References | Related Articles | Metrics
    Epilepsy is one of the five major neuropsychiatric diseases that the World Health Organization focuses on. There are more than 10 million people with epilepsy in China, which lead to tremendous burden of disease. Fortunately, over 70% of epilepsy patients can achieve the treatment goal of seizure control and reintegration into society under standardized treatment. Improving the qualityof diagnosis and treatment of epilepsy can effectively improve the accessibility of medical care in people with epilepsy in China. In 2017, with the support of the National Health Commission, the National Center for Healthcare Quality Management in Neurological Diseases set up the Epilepsy Medical Working Group to start the construction of the medical quality control system in epilepsy and convulsive status epilepticus. The construction of medical quality control system for epilepsy and convulsive status epilepticus strengthened the national epilepsy management system, found out the status of diagnosis and treatment in China, built a dynamic feedback mechanism for the medical quality system with multiple data sources complementing each other. Applying medical quality tools for epilepsy and convulsive status epilepticus, which have continued to promote the homogenization of epilepsy diagnosis and treatment in China.
    Medical Quality Control Indicators for Epilepsy and Convulsive Status Epilepticus
    The Epilepsy Working Group of National Center for Healthcare Quality Management in Neurological Diseases
    2024, 19(1):  58-65.  DOI: 10.3969/j.issn.1673-5765.2024.01.008
    Asbtract ( )   PDF (1525KB) ( )  
    References | Related Articles | Metrics
    Epilepsy is one of the five major neuropsychiatric diseases that the World Health Organization (WHO) focuses on prevention and treatment. From June 2017 to the present, the Epilepsy Working Group of National Center for Healthcare Quality Management in Neurological Diseases has launched the national epilepsy medical quality indicator system after three batches of pilots, based on full reference to domestic and overseas evidence-based evidence and previous indicator experience. It has built a medical quality control system for epilepsy and convulsive status epilepticus covering 130 sentinel hospitals in 31 provincial administrative regions across China. Regarding on the diagnosis and treatment indicator data feedback from sentinel hospitals, the system was revised based on the published quality control indicators. Twenty validated indicators in epilepsy and convulsive status epilepticus were included. In 2020, the General Office of the National Health Commission issued the indicator system. Disease quality control indicators rely on the national quality control network system to implement medical quality control and management, aiming at improving medical quality and promoting the homogenization of diagnosis and treatment. Currently, this indicator system has been incorporated into the accreditation standards for tertiary hospitals. In addition to strengthening the training, analysis and feedback of information on the indicators, the standardized diagnosis and treatment of epilepsy and convulsive status epilepticus in medical institutions at all levels are constantly promoted.
    Establish a Medical Standard and Continuous Quality Improvement System for Motor Neuron Disease in China
    HE Ji, FAN Dongsheng
    2024, 19(1):  66-68.  DOI: 10.3969/j.issn.1673-5765.2024.01.009
    Asbtract ( )   PDF (1704KB) ( )  
    References | Related Articles | Metrics
    Motor neuron disease (MND) is a group of neurodegenerative diseases, with amyotrophic lateral sclerosis (ALS) being the primary type of MND. At present, ALS/MND lacks specific diagnosis and treatment methods, and the prognosis of patients is poor. Although ALS/MND is rare, there is a rapid increase in the number of hospitalized patients in China. Considering the practical situation in China, there is an urgent need for standardized medical quality control system of ALS/MND. The National Center for Healthcare Quality Management in Neurological Diseases set up the MND Working Group in 2022 and initiated the construction of a clinical quality control system for ALS/MND. Through systematic research, the MND Working Group formulated the core concept of “establishing a medical standard and continuous quality improvement system for MND in China” and utilized the Delphi method to develop quality control indicators in ALS. This includes systematic quality control of the inpatient diagnosis and treatment process of ALS, covering unified diagnostic standards, a comprehensive patient management approach, and standardized treatment protocols. Beyond quality control indicators, the working group also carried out the work of promoting the core data elements of clinical diagnosis and treatment, the construction of the MND quality control information platform, and ensuring the consistency of clinical practice through a national series of standardized teaching sessions. The quality control program should be dynamic, and the working group will integrate practical considerations to ensure the effectiveness and feasibility of the quality control measures in real-world applications. In the future, the continuous development and refinement of this system will provide a scientific and standardized quality control system for the clinical diagnosis and treatment of ALS/MND.
    Medical Quality Control Indicators for Amyotrophic Lateral Sclerosis 
    The Motor Neuron Disease Working Group of National Center for Healthcare Quality Management in Neurological Diseases
    2024, 19(1):  69-75.  DOI: 10.3969/j.issn.1673-5765.2024.01.010
    Asbtract ( )   PDF (1552KB) ( )  
    References | Related Articles | Metrics
    In 2022, the National Center for Healthcare Quality Management in Neurological Diseases set up the Motor Neuron Disease (MND) Working Group and started the construction of medical quality control system for amyotrophic lateral sclerosis (ALS) /MND. 
    Through systematic investigation of evidence-based medicine evidence and domestic and foreign guidelines, the working group formulated the ALS medical quality control indicator system by using Delphi method, and systematically improved the quality control process of ALS in patient diagnosis and treatment from the aspects of unifying diagnostic criteria, establishing the concept of comprehensive management and standardizing treatment plans. The system includes 15 indicators, which will provide the first set of quantitative tools for monitoring the implementation of medical quality improvement of ALS in China. Through the continuous monitoring of this indicators system, the systematic comparison of treatment quality control could be carried out. With the help of this quality control system, medical staff can improve their understanding of ALS, and clinical medical behaviors can be standardized, thus establishing medical standards and continuous quality improvement system for MND in China.
    Prediction Models of Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke: A Systematic Review
    YANG Jiaxin, HE Chunyu, LIU Lei, CHEN Wenbo, XIE Yan
    2024, 19(1):  76-86.  DOI: 10.3969/j.issn.1673-5765.2024.01.011
    Asbtract ( )   PDF (2224KB) ( )  
    References | Related Articles | Metrics
    Objective  To systematically evaluate the prediction models of symptomatic intracerebral hemorrhage after intravenous thrombolysis in acute ischemic stroke and to provide a reference for clinical decision-making of intravenous thrombolysis.
    Methods  CNKI, WanFang Data, VIP, PubMed, Embase, Web of Science, and The Cochrane Library databases were searched to collect relevant studies, with a timeframe for searching the database from the establishment of the database to December 18, 2022. Two researchers independently screened the literature, extracted the data, assessed the risk of bias, and then systematically evaluated the basic characteristics and methodology of the included models. 
    Results  Twenty studies were included, with a total of 30 prediction models. The AUC of the included models ranged from 0.42 to 0.94. The overall predictive performance of the 24 (80%) prediction models was good, with significant differences in model differentiation across outcome definitions and algorithms. The most common predictors were NIHSS score, age, imaging signs or scores of infarction, blood glucose, systolic blood pressure, and antiplatelet drugs.
    Conclusions  In recent years, the prediction models of symptomatic intracerebral hemorrhage after intravenous thrombolysis in acute ischemic stroke have shown the characteristics of diversified modeling algorithms, better model performance, and diversified predictors. However, the overall risk of bias was high, and future studies need to calibrate the models further. More attention should be paid to updating and externally validating the models to improve extrapolation and clinical utility and utilize the models’ clinical practice implications.
    Predictive Research Progress on Shunt-Dependent Hydrocephalus after Aneurysmal Subarachnoid Hemorrhage
    WANG Chao, HU Yongzhen, LI Xuesong
    2024, 19(1):  87-93.  DOI: 10.3969/j.issn.1673-5765.2024.01.012
    Asbtract ( )   PDF (1491KB) ( )  
    References | Related Articles | Metrics
    Aneurysmal subarachnoid hemorrhage is a common neurosurgical disease. Its high mortality and disability rate and numerous complications bring a heavy burden to patients and society. Shunt-dependent hydrocephalus is one of the complications of this disease. Some patients may have no symptoms in the early stage of the disease, making it difficult to diagnose, leading to poor prognosis or even death. With the continuous progress of research, many indicators that have predictive value for shunt-dependent hydrocephalus have been reported in the literature. This paper aims to review these predictive indicators to help clinicians identify the patients with high risk of shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage early, and take active intervention measures to improve the prognosis of patients.
    Clinical Advances in Hemorrhagic Transformation after Mechanical Thrombectomy for Acute Ischemic Stroke due to Large Vessel Occlusion
    KANG Zhiming, MEI Bin
    2024, 19(1):  94-104.  DOI: 10.3969/j.issn.1673-5765.2024.01.013
    Asbtract ( )   PDF (1530KB) ( )  
    References | Related Articles | Metrics
    Mechanical thrombectomy is the standard treatment for acute ischemic stroke due to large vessel occlusion in the anterior circulation within 24 hours of onset, and hemorrhagic transformation is the most common and serious complication, which not only increases the length of hospital stay, but also leads to a poor prognosis and negates the benefits of mechanical thrombectomy. Therefore, it is of great importance to scientifically understand this complication. Recently, domestic and foreign scholars have carried out extensive investigations on the hemorrhagic transformation after mechanical thrombectomy. In this paper, the definition, classification, incidence, risk factors, prevention and management of hemorrhagic transformation were reviewed based on domestic and foreign literatures.
    Current Research in the Mechanism and Clinical Application about Remote Ischemic Preconditioning in Cerebral Infarction
    LIU Xudong, LIU Meng, SU Ying, ZHOU Yanxia, REN Lijie
    2024, 19(1):  105-111.  DOI: 10.3969/j.issn.1673-5765.2024.01.014
    Asbtract ( )   PDF (1523KB) ( )  
    References | Related Articles | Metrics
    Cerebral infarction is one of the diseases with high rates of disability and death worldwide, but there is still a lack of more effective treatments. Many studies showed that remote ischemic preconditioning (RIPC) can significantly improve ischemic tolerance of target organs, reduce infarct size and improve prognosis. However, its role and mechanism in the development of cerebral infarction are still little studied. This paper will summarize the role and mechanism of RIPC in cerebral infarction from the following aspects: neural, humoral, immune and related signaling pathways, and review the current research progress of RIPC in clinical cerebral ischemic diseases to provide a reference for subsequent research.
    A Three-Dimensional Measurement Method of Morphological Indicators of Unruptured Intracranial Aneurysm Based on Artificial Intelligence
    YANG Yi, LIU Qingyuan, LIU Weiqi, WANG Shuo
    2024, 19(1):  112-119.  DOI: 10.3969/j.issn.1673-5765.2024.01.015
    Asbtract ( )   PDF (2259KB) ( )  
    References | Related Articles | Metrics
    Morphological analysis of unruptured intracranial aneurysms is widely used in risk assessment and surgical design. Compared with the manual measurement in the two-dimensional perspective, the three-dimensional perspective can reflect the morphology changes of aneurysms more accurately. But the manual measurement in the three-dimensional perspective has poor accuracy and repeatability. Therefore, the measurement of artificial intelligence in the three-dimensional perspective has greater advantages than that of manual measurement. However, the method of aneurysm morphological measurement in the three-dimensional perspective based on artificial intelligence has not been proposed. The standardized measurement in the three-dimensional perspective is of great significance to the clinical and research application of morphological parameters. In this paper, a three-dimensional measurement method for unruptured intracranial aneurysms based on artificial intelligence is presented, in order to promote the homogenization of aneurysm research and the standardization of clinical diagnosis and treatment.
    Research on the Influence of Cerebrovascular Disease Clinical Decision Support System on the Key Performance Indicators of Medical Care Quality for Stroke
    ZHANG Xinmiao, XU Man, DING Lingling, JING Jing, GONG Xiping, DONG Kehui, ZHAO Xingquan, WANG Yongjun, LI Zixiao
    2024, 19(1):  120-124.  DOI: 10.3969/j.issn.1673-5765.2024.01.016
    Asbtract ( )   PDF (2100KB) ( )  
    References | Related Articles | Metrics
    Objective  This study aimed to explore whether cerebrovascular disease clinical decision support system (CDSS) could improve the key performance indicators of medical care quality.
    Methods  In our study, ischemic stroke patients hospitalized in Ward 2 of Vascular Neurology, Beijing Tiantan Hospital, Capital Medical University before applying cerebrovascular disease CDSS (January to November 2020) were retrospectively included as the control group. Ischemic stroke patients admitted after the application of CDSS assisted diagnosis and treatment (January to November 2021) were included as the intervention group. The baseline characteristics and key performance indicators of medical care quality for ischemic stroke in these two groups were compared to assess the impact of cerebrovascular disease CDSS on medical care quality of stroke. 
    Results  A total of 1331 patients were included in this study, including 651 in the control group and 680 in the intervention group. The mean age of the control group was (71.7±11.8) years, with 490 males (75.3%), and the mean age of the intervention group was (72.3±10.2) years, with 498 males (73.2%). Among the key performance indicators of medical care quality of ischemic stroke, the proportion of patients who were unable to walk within 48 h of admission received deep vein thrombosis prevention (86.3% vs. 65.0%, P<0.01), the rate of patients who were discharged with antithrombotic therapy (98.1% vs. 96.2%, P=0.03), and the rate of patients with atrial fibrillation with anticoagulation therapy (70.1% vs. 44.2%, P<0.01) in the intervention group were higher than those in control group. 
    Conclusions  Cerebrovascular disease CDSS can improve the key performance indicators of medical care quality in patients with ischemic stroke.